675 related articles for article (PubMed ID: 2473403)
1. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Cardiac Arrhythmia Suppression Trial (CAST) Investigators
N Engl J Med; 1989 Aug; 321(6):406-12. PubMed ID: 2473403
[TBL] [Abstract][Full Text] [Related]
2. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
Cardiac Arrhythmia Pilot Study (CAPS) Investigators
Am J Cardiol; 1988 Mar; 61(8):501-9. PubMed ID: 2894169
[TBL] [Abstract][Full Text] [Related]
3. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST).
Anderson JL; Platia EV; Hallstrom A; Henthorn RW; Buckingham TA; Carlson MD; Carson PE
Circulation; 1994 Dec; 90(6):2843-52. PubMed ID: 7994829
[TBL] [Abstract][Full Text] [Related]
4. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Echt DS; Liebson PR; Mitchell LB; Peters RW; Obias-Manno D; Barker AH; Arensberg D; Baker A; Friedman L; Greene HL
N Engl J Med; 1991 Mar; 324(12):781-8. PubMed ID: 1900101
[TBL] [Abstract][Full Text] [Related]
5. Treatment of ventricular arrhythmias after CAST.
Tonkin AM
Med J Aust; 1992 Apr; 156(7):488-92. PubMed ID: 1372950
[TBL] [Abstract][Full Text] [Related]
6. Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy.
Bigger JT; Rolnitzky LM; Steinman RC; Fleiss JL
J Am Coll Cardiol; 1994 Mar; 23(3):733-40. PubMed ID: 7509355
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
Akiyama T; Pawitan Y; Greenberg H; Kuo CS; Reynolds-Haertle RA
Am J Cardiol; 1991 Dec; 68(17):1551-5. PubMed ID: 1720917
[TBL] [Abstract][Full Text] [Related]
8. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.
Bigger JT
Am J Cardiol; 1990 Feb; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253
[TBL] [Abstract][Full Text] [Related]
9. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled.
Epstein AE; Bigger JT; Wyse DG; Romhilt DW; Reynolds-Haertle RA; Hallstrom AP
J Am Coll Cardiol; 1991 Jul; 18(1):14-9. PubMed ID: 1904891
[TBL] [Abstract][Full Text] [Related]
10. Lessons from the cardiac arrhythmia suppression trial.
Garratt C; Ward DE; Camm AJ
BMJ; 1989 Sep; 299(6703):805-6. PubMed ID: 2510839
[No Abstract] [Full Text] [Related]
11. Relation of baseline characteristics to suppression of ventricular arrhythmias during placebo and active antiarrhythmic therapy in patients after myocardial infarction.
Anderson JL; Hallstrom AP; Griffith LS; Ledingham RB; Reiffel JA; Yusuf S; Barker AH; Fowles RE; Young JB
Circulation; 1989 Mar; 79(3):610-9. PubMed ID: 2465099
[TBL] [Abstract][Full Text] [Related]
12. Recruitment and baseline description of patients in the Cardiac Arrhythmia Pilot Study. The Cardiac Arrhythmia Pilot Study (CAPS) investigators.
Am J Cardiol; 1988 Apr; 61(10):704-13. PubMed ID: 2451414
[TBL] [Abstract][Full Text] [Related]
13. Encainide--an updated safety profile.
Thomis JA
Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():585-94. PubMed ID: 2125837
[TBL] [Abstract][Full Text] [Related]
14. Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study).
Greene HL; Richardson DW; Hallstrom AP; McBride R; Capone RJ; Barker AH; Roden DM; Echt DS
Am J Cardiol; 1989 Feb; 63(7):393-8. PubMed ID: 2464919
[TBL] [Abstract][Full Text] [Related]
15. The cardiac arrhythmia suppression trial (CAST).
Ruskin JN
N Engl J Med; 1989 Aug; 321(6):386-8. PubMed ID: 2501683
[No Abstract] [Full Text] [Related]
16. The Cardiac Arrhythmia Suppression Trial: Implications for nursing practice.
Kellen JC; Ettinger A; Todd L; Brezsnyak ML; Campion J; McBride R; Thomas S; Corum J; Schron E
Am J Crit Care; 1996 Jan; 5(1):19-25. PubMed ID: 8680488
[TBL] [Abstract][Full Text] [Related]
17. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST).
Epstein AE; Hallstrom AP; Rogers WJ; Liebson PR; Seals AA; Anderson JL; Cohen JD; Capone RJ; Wyse DG
JAMA; 1993 Nov; 270(20):2451-5. PubMed ID: 8230622
[TBL] [Abstract][Full Text] [Related]
18. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias.
Pritchett EL; Wilkinson WE
Am J Cardiol; 1991 May; 67(11):976-80. PubMed ID: 1902055
[TBL] [Abstract][Full Text] [Related]
19. The events surrounding the removal of encainide and flecainide from the Cardiac Arrhythmia Suppression Trial (CAST) and why CAST is continuing with moricizine.
Bigger JT
J Am Coll Cardiol; 1990 Jan; 15(1):243-5. PubMed ID: 2104884
[No Abstract] [Full Text] [Related]
20. The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II.
Greene HL; Roden DM; Katz RJ; Woosley RL; Salerno DM; Henthorn RW
J Am Coll Cardiol; 1992 Apr; 19(5):894-8. PubMed ID: 1552108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
